Kelley's Optical & Boutique

06/05/2026

CAMBRIDGE, Mass.—Luminopia Inc., a digital health company pioneering a new class of treatments for neuro-visual disorders, announced its first international licensing agreement with ROHTO Pharmaceutical Co. Ltd., a Japanese multinational corporation specializing in consumer products and pharmaceuticals, with a primary focus on eyecare. The agreement grants ROHTO exclusive rights to develop and commercialize Luminopia’s digital therapy for pediatric amblyopia in the Japanese market.

CAMBRIDGE, Mass.—Luminopia Inc., a digital health company pioneering a new class of treatments for neuro-visual disorders, announced its first international licensing agreement with ROHTO Pharmaceutical Co. Ltd., a Japanese multinational corporation specializing in consumer products and pharmaceut...

06/05/2026

NEWARK, N.J.—The readers of Vision Monday and 20/20 magazine are being asked once again to share nominations for their Ultimate Partners, but time is running out—the deadline for submissions is today, June 5, at 11:59 pm ET. Now in its sixth year, Jobson’s 2026 Ultimate Partners program allows readers to highlight their great business support partners and showcase their assistance. Open to all eyecare professionals, the program is looking to spotlight your most successful collaborations and celebrate the crucial support shared during both challenges and opportunities. Our ever-changing workplace renders partnership more vital than ever, and we want to hear your teamwork success stories.

NEWARK, N.J.—The readers of Vision Monday and 20/20 magazine are being asked once again to share nominations for their Ultimate Partners, but time is running out—the deadline for submissions is today, June 5, at 11:59 pm ET. Now in its sixth year, Jobson’s 2026 Ultimate Partners program allows...

06/03/2026

NEWARK, N.J.—The readers of Vision Monday and 20/20 magazine are being asked once again to share nominations for their Ultimate Partners, but time is running out—the deadline for submissions is Friday, June 5. Now in its sixth year, Jobson’s 2026 Ultimate Partners program allows readers to highlight their great business support partners and showcase their assistance. Open to all eyecare professionals, the program is looking to spotlight your most successful collaborations and celebrate the crucial support shared during both challenges and opportunities. Our ever-changing workplace renders partnership more vital than ever, and we want to hear your teamwork success stories.

NEWARK, N.J.—The readers of Vision Monday and 20/20 magazine are being asked once again to share nominations for their Ultimate Partners, but time is running out—the deadline for submissions is Friday, June 5. Now in its sixth year, Jobson’s 2026 Ultimate Partners program allows readers to hig...

06/02/2026

MIAMI—The University of Miami School of Medicine has announced the appointment of Pradeep Y. Ramulu, MD, MHS, Ph.D., as chair of the department of ophthalmology and the Bascom Palmer Eye Institute, effective August 3, 2026. Dr. Ramulu is a Bascom Palmer alumnus who “returns to lead the institution where his career in glaucoma was shaped, bringing with him nearly two decades of transformative clinical, research and educational leadership from the Wilmer Eye Institute at Johns Hopkins University,” the Institute said in an announcement. As chair, Dr. Ramulu will hold the Kathleen and Stanley J. Glaser chair in ophthalmology.

MIAMI—The University of Miami School of Medicine has announced the appointment of Pradeep Y. Ramulu, MD, MHS, Ph.D., as chair of the department of ophthalmology and the Bascom Palmer Eye Institute, effective August 3, 2026. Dr. Ramulu is a Bascom Palmer alumnus who “returns to lead the instituti...

05/26/2026

NEWARK, N.J.—The readers of Vision Monday and 20/20 magazine are being asked once again to share nominations for their Ultimate Partners. The deadline for submissions is June 5. Now in its sixth year, Jobson’s 2026 Ultimate Partners program allows readers to highlight their great business support partners and showcase their assistance. Open to all eyecare professionals, the program is looking to spotlight your most successful collaborations and celebrate the crucial support shared during both challenges and opportunities. Our ever-changing workplace renders partnership more vital than ever, and we want to hear your teamwork success stories.

NEWARK, N.J.—The readers of Vision Monday and 20/20 magazine are being asked once again to share nominations for their Ultimate Partners. The deadline for submissions is June 5. Now in its sixth year, Jobson’s 2026 Ultimate Partners program allows readers to highlight their great business suppor...

05/14/2026

05/13/2026

NEWARK, N.J.—The readers of Vision Monday and 20/20 magazine are being asked once again to share nominations for their Ultimate Partners. The deadline for submissions is June 5. Now in its sixth year, Jobson’s 2026 Ultimate Partners program allows readers to highlight their great business support partners and showcase their assistance. Open to all eyecare professionals, the program is looking to spotlight your most successful collaborations and celebrate the crucial support shared during both challenges and opportunities. Our ever-changing workplace renders partnership more vital than ever, and we want to hear your teamwork success stories.

NEWARK, N.J.—The readers of Vision Monday and 20/20 magazine are being asked once again to share nominations for their Ultimate Partners. The deadline for submissions is June 5. Now in its sixth year, Jobson’s 2026 Ultimate Partners program allows readers to highlight their great business suppor...

05/13/2026

LOS ANGELES—LensCrafters and the OneSight EssilorLuxottica Foundation have partnered to help more than 900 Los Angeles Unified School District students in grades K-12 receive the gift of clear sight during a five-day vision clinic held this month at Harry Bridges Span School in Wilmington, according to an announcement from EssilorLuxottica. More than 80 volunteers, including LensCrafters, EyeMed and additional EssilorLuxottica team members, along with volunteer optometrists, technicians and support staff, worked together to provide free eye exams and prescription glasses to students who may otherwise lack access to essential vision care.

LOS ANGELES—LensCrafters and the OneSight EssilorLuxottica Foundation have partnered to help more than 900 Los Angeles Unified School District students in grades K-12 receive the gift of clear sight during a five-day vision clinic held this month at Harry Bridges Span School in Wilmington, accordi...

05/11/2026

BERLIN and SAN FRANCISCO—Bayer and Perfuse Therapeutics Inc. have announced an agreement under which Bayer said it will fully acquire Perfuse Therapeutics, a biopharmaceutical company pioneering transformational research into the treatment of ischemia-induced ocular diseases. With this acquisition, Bayer, a global enterprise with core competencies in the life science fields of health care and nutrition, will hold the full rights pertaining to PER-001, a small molecule endothelin receptor antagonist currently in phase II clinical development for the treatment of glaucoma and diabetic retinopathy, the announcement said. The acquisition is subject to and will become effective after receiving the necessary antitrust clearances and approvals from Perfuse stockholders, the two companies stated.

BERLIN and SAN FRANCISCO—Bayer and Perfuse Therapeutics Inc. have announced an agreement under which Bayer said it will fully acquire Perfuse Therapeutics, a biopharmaceutical company pioneering transformational research into the treatment of ischemia-induced ocular diseases. With this acquisition...

05/08/2026

WATERTOWN, Mass.—EyePoint, Inc. (Nasdaq: EYPT), a clinical-stage biopharmaceutical company developing therapeutics for retinal diseases, announced financial results for the first quarter ended March 31, 2026, and highlighted recent corporate developments. For the first quarter, total net revenue was $0.7 million, compared with $24.5 million for the same period in 2025. The decrease was primarily driven by the recognition of remaining deferred revenue related to the company’s 2023 agreement for the license of Yutiq product rights, a treatment for chronic non-infectious uveitis, the announcement said. EyePoint also reported net nonoperating income totaling $2.3 million and a net loss of $84.8 million, compared with a net loss of $45.2 million for the same period in 2025.

WATERTOWN, Mass.—EyePoint, Inc. (Nasdaq: EYPT), a clinical-stage biopharmaceutical company developing therapeutics for retinal diseases, announced financial results for the first quarter ended March 31, 2026, and highlighted recent corporate developments. For the first quarter, total net revenue w...